相似文献
1
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2.
2
TP53 mutation and survival in chronic lymphocytic leukemia.
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
3
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Eur J Haematol. 2016 Jan;96(1):9-18. doi: 10.1111/ejh.12678. Epub 2015 Nov 6.
4
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Hum Mutat. 2014 Jun;35(6):663-71. doi: 10.1002/humu.22508. Epub 2014 Feb 5.
5
Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Int J Cancer. 2016 Nov 15;139(10):2252-60. doi: 10.1002/ijc.30263. Epub 2016 Aug 2.
6
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
Leuk Res. 2021 Nov;110:106663. doi: 10.1016/j.leukres.2021.106663. Epub 2021 Jul 6.
7
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132.
8
Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.
Br J Haematol. 2017 Sep;178(6):979-982. doi: 10.1111/bjh.14176. Epub 2016 Jul 29.
9
Targeting p53 in chronic lymphocytic leukemia.
Expert Opin Ther Targets. 2020 Dec;24(12):1239-1250. doi: 10.1080/14728222.2020.1832465. Epub 2020 Oct 19.
10
Tumor suppressor genes and clonal evolution in B-CLL.
Leuk Lymphoma. 1995 Jun;18(1-2):41-9. doi: 10.3109/10428199509064921.
引用本文的文献
1
Detection of clinically relevant variants in the gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Hemasphere. 2025 Jan 20;9(1):e70065. doi: 10.1002/hem3.70065. eCollection 2025 Jan.
2
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
Blood Cancer J. 2024 Feb 21;14(1):33. doi: 10.1038/s41408-024-01001-1.
3
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.
Cancer Drug Resist. 2020 May 11;3(3):532-549. doi: 10.20517/cdr.2019.111. eCollection 2020.
4
Impact of Low-Burden Mutations in the Management of CLL.
Front Oncol. 2022 Feb 8;12:841630. doi: 10.3389/fonc.2022.841630. eCollection 2022.
5
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Nat Commun. 2021 Sep 13;12(1):5395. doi: 10.1038/s41467-021-25403-y.
6
The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.
Nat Rev Clin Oncol. 2022 Jan;19(1):23-36. doi: 10.1038/s41571-021-00549-2. Epub 2021 Sep 10.
7
MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype.
Cancers (Basel). 2021 Sep 6;13(17):4484. doi: 10.3390/cancers13174484.
8
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Blood. 2021 Dec 23;138(25):2670-2685. doi: 10.1182/blood.2020009530.
9
New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data.
Front Genet. 2019 Sep 20;10:854. doi: 10.3389/fgene.2019.00854. eCollection 2019.
10
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Cell Syst. 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003.
本文引用的文献
1
Telomere dysfunction and chromothripsis.
Int J Cancer. 2016 Jun 15;138(12):2905-14. doi: 10.1002/ijc.30033. Epub 2016 Feb 29.
2
Mutations driving CLL and their evolution in progression and relapse.
Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14.
3
Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis.
Leukemia. 2015 Mar;29(3):758. doi: 10.1038/leu.2014.309.
4
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.
J Exp Med. 2013 Oct 21;210(11):2273-88. doi: 10.1084/jem.20131448. Epub 2013 Oct 14.
5
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.
Blood. 2013 Oct 10;122(15):2673-82. doi: 10.1182/blood-2013-03-489518. Epub 2013 Sep 4.
6
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Clin Cancer Res. 2013 Jun 1;19(11):2893-904. doi: 10.1158/1078-0432.CCR-13-0138. Epub 2013 Apr 25.
7
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Cell. 2013 Feb 14;152(4):714-26. doi: 10.1016/j.cell.2013.01.019.
8
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
Blood. 2012 Dec 6;120(24):4783-94. doi: 10.1182/blood-2012-04-423517. Epub 2012 Oct 9.
9
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.
10
Clonal evolution in cancer.
Nature. 2012 Jan 18;481(7381):306-13. doi: 10.1038/nature10762.
Zotero 插件